CA Patent

CA3190636A1 — Ophthalmic compositions for removing meibum or inhibiting meibum buildup

Assigned to Altaire Pharmaceuticals Inc · Expires 2022-02-03 · 4y expired

What this patent protects

Microemulsion formulations containing polyoxyethylene castor oil derivatives (such as polyoxyl 35 castor oil) contain nanoparticle micelles and are capable of dissolving/absorbing meibum materials. By removing obstructive meibum materials that may be positioned in the orifice of …

USPTO Abstract

Microemulsion formulations containing polyoxyethylene castor oil derivatives (such as polyoxyl 35 castor oil) contain nanoparticle micelles and are capable of dissolving/absorbing meibum materials. By removing obstructive meibum materials that may be positioned in the orifice of meibomian gland channels, the present formulations provide a non-irritating treatment for meibomian gland dysfunction (MGD).

Drugs covered by this patent

Patent Metadata

Patent number
CA3190636A1
Jurisdiction
CA
Classification
—
Expires
2022-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Altaire Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.